Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer.

Steroid sulfatase (STS) hydrolyzes several sulfated steroids such as estrone sulfate, dehydroepiandrosterone sulfate, and cholesterol sulfate. In the present study, we have measured STS mRNA levels in 97 breast cancers by reverse transcription-PCR using a fluorescent primer in the presence of an internal standard RNA and evaluated its association with disease-free and overall survival. The median value was 728.0 amol/ng RNA (range, 0-11,778 amol/ng RNA). Levels were significantly higher in tumors demonstrating lymph node metastasis than in those without nodal involvement (P = 0.033) and in patients who experienced a recurrence during the follow-up period (mean, 40.8 months; median, 39 months) compared with those with no evidence of further disease (mean, 49.2 months; median, 48 months; P = 0.029). No significant associations were found between STS mRNA expression and age, menopausal status, tumor size, histological grade, estrogen receptor status, or postoperative adjuvant therapy. High levels of STS mRNA proved to be a significant predictor of reduced relapse-free survival as a continuous variable (log STS mRNA; P = 0.028). As a dichotomous variable with an optimized cutoff point of 1,240 amol/ng RNA, expression was also associated with a significantly shorter relapse-free survival rate (P = 0.002), but no significant correlation was found between the STS mRNA level and overall survival. Expression was found to be an independent factor for predicting relapse-free survival on multivariate analysis. The results thus support a putative role of STS in breast cancer growth and metastasis.

[1]  K. Selcer,et al.  Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines. , 1997, Cancer research.

[2]  B. Potter,et al.  In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor. , 1996, Cancer research.

[3]  Pui-Kai Li,et al.  Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  N. Harada,et al.  Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. , 1996, The Journal of clinical endocrinology and metabolism.

[5]  B. Potter,et al.  Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate. , 1995, Biochemistry.

[6]  G. Chetrite,et al.  Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  L. Dibbelt,et al.  Estrone sulfate analogs as estrone sulfatase inhibitors , 1995, Steroids.

[8]  M. Dowsett,et al.  Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. , 1994, Cancer research.

[9]  B. Potter,et al.  The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  B. Potter,et al.  Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: Potential therapeutic agents in breast cancer , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  R. Coombes,et al.  Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. , 1994, British Journal of Cancer.

[12]  B. Potter,et al.  Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. , 1994, Journal of medicinal chemistry.

[13]  R. Coombes,et al.  Detection of breast cancer-associated estrone sulfatase in breast cancer biopsies and cell lines using polymerase chain reaction , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  B. Ohlsson-Wilhelm,et al.  Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF‐7 cell cultures , 1993, International journal of cancer.

[15]  B. Potter,et al.  Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. , 1993, Cancer research.

[16]  W. McGuire,et al.  Cathepsin D and prognosis in breast cancer. , 1990, The New England journal of medicine.

[17]  H. Rochefort,et al.  Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. , 1989, Molecular endocrinology.

[18]  M. Hinkhouse,et al.  The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. , 1988, Endocrinology.

[19]  L. Dibbelt,et al.  Human placental steryl-sulfatase. Enzyme purification, production of antisera, and immunoblotting reactions with normal and sulfatase-deficient placentas. , 1986, Biological chemistry Hoppe-Seyler.

[20]  F. Labrie,et al.  Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. , 1986, Cancer research.

[21]  J. Deslypere,et al.  Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. , 1986, European journal of cancer & clinical oncology.

[22]  A. V. Landeghem,et al.  Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. , 1985, Cancer research.

[23]  R. Santen,et al.  In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. , 1984, The Journal of clinical endocrinology and metabolism.

[24]  G. Adessi,et al.  Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulfate levels in human breast carcinoma. , 1984, Cancer research.

[25]  G. Burns,et al.  Purification and partial characterization of arylsulphatase C from human placental microsomes. , 1983, Biochimica et biophysica acta.

[26]  G. Adessi,et al.  Estrone and dehydroepiandrosterone sulfatase activities in normal and pathological human endometrium biopsies. , 1983, The Journal of clinical endocrinology and metabolism.

[27]  H. Jacobs,et al.  The plasma concentration of oestrone sulphate in postmenopausal women: lack of diurnal variation, effect of ovariectomy, age and weight. , 1981, Journal of steroid biochemistry.

[28]  H. Rochefort,et al.  A secreted glycoprotein induced by estrogen in human breast cancer cell lines , 1980, Cell.

[29]  H. Rochefort,et al.  Effects of plasma estrogen sulfates in mammary cancer cells. , 1980, Endocrinology.

[30]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[31]  R. Santen,et al.  Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. , 1978, The Journal of clinical endocrinology and metabolism.

[32]  M. DeLaGarza,et al.  Evaluation of estrogen receptor assays in human breast cancer tissue. , 1977 .

[33]  D. Millington.  Determination of hormonal steroid concentrations in biological extracts by high resolution mass fragmentography. , 1975, Journal of steroid biochemistry.

[34]  H. Ruder,et al.  Estrone sulfate: production rate and metabolism in man. , 1972, The Journal of clinical investigation.

[35]  P. Libby,et al.  Conjugation of steroid hormones by normal and neoplastic tissues. , 1968, The Journal of clinical endocrinology and metabolism.

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[37]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[38]  T. Powles,et al.  Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. , 1994, European journal of cancer.

[39]  P. Dombernowsky,et al.  Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A. , 1994, European journal of cancer.

[40]  A. Purohit,et al.  Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. , 1990, Cancer research.

[41]  J. Pasqualini,et al.  Importance of estrogen sulfates in breast cancer. , 1989, Journal of steroid biochemistry.

[42]  M. Edery,et al.  Endogenous oestradiol-17beta concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. , 1981, European journal of cancer.

[43]  D.,et al.  Regression Models and Life-Tables , 2022 .